Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-2)

Engensis (donaperminogene seltoplasmid) - Beijing Northland, Reyon Pharma, Helixmith

http://clinicaltrials.gov/ct2/show/NCT04274049

Mar 31, 2022